Lytix Biopharma AS (LYTIX) - Net Assets
Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has net assets worth Nkr61.75 Million NOK (≈ $6.50 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr81.52 Million ≈ $8.58 Million USD) and total liabilities (Nkr19.77 Million ≈ $2.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LYTIX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr61.75 Million |
| % of Total Assets | 75.74% |
| Annual Growth Rate | 23.0% |
| 5-Year Change | -67.44% |
| 10-Year Change | N/A |
| Growth Volatility | 290.54 |
Lytix Biopharma AS - Net Assets Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Lytix Biopharma AS for the complete picture of this company's asset base.
Annual Net Assets for Lytix Biopharma AS (2017–2025)
The table below shows the annual net assets of Lytix Biopharma AS from 2017 to 2025. For live valuation and market cap data, see LYTIX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr61.75 Million ≈ $6.50 Million |
-42.77% |
| 2024-12-31 | Nkr107.89 Million ≈ $11.35 Million |
+110.24% |
| 2023-12-31 | Nkr51.32 Million ≈ $5.40 Million |
-62.02% |
| 2022-12-31 | Nkr135.13 Million ≈ $14.22 Million |
-28.74% |
| 2021-12-31 | Nkr189.62 Million ≈ $19.95 Million |
+853.41% |
| 2020-12-31 | Nkr19.89 Million ≈ $2.09 Million |
+46.46% |
| 2019-12-31 | Nkr13.58 Million ≈ $1.43 Million |
-66.92% |
| 2018-12-31 | Nkr41.05 Million ≈ $4.32 Million |
+248.18% |
| 2017-12-31 | Nkr11.79 Million ≈ $1.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Lytix Biopharma AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr6.83 Million | 11.05% |
| Other Components | Nkr54.92 Million | 88.95% |
| Total Equity | Nkr61.75 Million | 100.00% |
Lytix Biopharma AS Competitors by Market Cap
The table below lists competitors of Lytix Biopharma AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Embellence Group AB
ST:EMBELL
|
$89.42 Million |
|
Agrify Corp
NASDAQ:AGFY
|
$89.44 Million |
|
AGF A/S
CO:AGF-B
|
$89.44 Million |
|
Toma as
PR:TOMA
|
$89.46 Million |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
$89.40 Million |
|
Ardea Resources Ltd
AU:ARL
|
$89.39 Million |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
$89.37 Million |
|
Kjell Group AB
ST:KJELL
|
$89.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lytix Biopharma AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 107,894,000 to 61,750,000, a change of -46,144,000 (-42.8%).
- Net loss of 59,982,000 reduced equity.
- Other factors increased equity by 13,838,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-59.98 Million | -97.14% |
| Other Changes | Nkr13.84 Million | +22.41% |
| Total Change | Nkr- | -42.77% |
Book Value vs Market Value Analysis
This analysis compares Lytix Biopharma AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 36.31x to 12.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Nkr0.30 | Nkr11.05 | x |
| 2018-12-31 | Nkr1.06 | Nkr11.05 | x |
| 2019-12-31 | Nkr0.35 | Nkr11.05 | x |
| 2020-12-31 | Nkr0.51 | Nkr11.05 | x |
| 2021-12-31 | Nkr4.89 | Nkr11.05 | x |
| 2022-12-31 | Nkr3.37 | Nkr11.05 | x |
| 2023-12-31 | Nkr1.26 | Nkr11.05 | x |
| 2024-12-31 | Nkr1.58 | Nkr11.05 | x |
| 2025-12-31 | Nkr0.90 | Nkr11.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lytix Biopharma AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-97.14%) is above the historical average (-174.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -537.37% | -5982.63% | 0.02x | 3.99x | Nkr-64.53 Million |
| 2018 | -149.85% | -18253.71% | 0.01x | 1.43x | Nkr-65.62 Million |
| 2019 | -244.68% | -10718.39% | 0.02x | 1.28x | Nkr-34.59 Million |
| 2020 | -211.61% | -1402933.33% | 0.00x | 1.64x | Nkr-44.08 Million |
| 2021 | -25.34% | -282641.18% | 0.00x | 1.07x | Nkr-67.01 Million |
| 2022 | -41.45% | -3974.88% | 0.01x | 1.13x | Nkr-69.52 Million |
| 2023 | -171.28% | -2202.38% | 0.06x | 1.24x | Nkr-93.03 Million |
| 2024 | -87.37% | -846.64% | 0.08x | 1.36x | Nkr-105.05 Million |
| 2025 | -97.14% | 0.00% | 0.00x | 1.32x | Nkr-66.16 Million |
Industry Comparison
This section compares Lytix Biopharma AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $119,120,746
- Average return on equity (ROE) among peers: -285.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lytix Biopharma AS (LYTIX) | Nkr61.75 Million | -537.37% | 0.32x | $89.42 Million |
| Arcticzymes Technologies ASA (AZT) | $244.84 Million | 18.94% | 0.16x | $107.48 Million |
| Bergenbio ASA (BGBIO) | $122.70 Million | -113.51% | 0.27x | $7.75 Million |
| Circio Holding ASA (CRNA) | $-12.49 Million | 0.00% | 0.00x | $225.78 Million |
| Exact Therapeutics AS (EXTX) | $45.10 Million | -107.17% | 0.36x | $9.79 Million |
| Nykode Therapeutics ASA (NYKD) | $242.56 Million | -49.57% | 0.21x | $112.71 Million |
| Oncoinvent ASA (ONCIN) | $108.33 Million | -128.57% | 0.58x | $21.68 Million |
| PCI Biotech Holding ASA (PCIB) | $254.83 Million | -34.83% | 0.11x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $2.37 Million | -1667.07% | 40.09x | $29.83 Million |
| Thor Medical ASA (TRMED) | $63.84 Million | -487.52% | 0.72x | $168.67 Million |
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more